WO1994011000A1 - Xanthinderivate als diuretisches mittel - Google Patents
Xanthinderivate als diuretisches mittel Download PDFInfo
- Publication number
- WO1994011000A1 WO1994011000A1 PCT/EP1993/003158 EP9303158W WO9411000A1 WO 1994011000 A1 WO1994011000 A1 WO 1994011000A1 EP 9303158 W EP9303158 W EP 9303158W WO 9411000 A1 WO9411000 A1 WO 9411000A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- propyl
- methyl
- diuretic
- benzyl
- Prior art date
Links
- FTNJQNQLEGKTGD-UHFFFAOYSA-N C1Oc(cccc2)c2O1 Chemical compound C1Oc(cccc2)c2O1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N C1Oc2ccccc2OC1 Chemical compound C1Oc2ccccc2OC1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Definitions
- the present invention relates to the use of 8- (3-oxocyclopentyl) -1,3-dipropyl 7H-purine-2, 6- .dione and structure-like xanthines as diuretics.
- Diuretics play an important role in the treatment of edema, hypertension and other diseases.
- All animals received an oral water load of 5 ml / 100 g body weight using a pharyngeal tube.
- KFM 19 was dissolved in water and administered together with the water load (1 ml solution, 4 ml water) orally in doses of 0.01, 0.03, 0.1 and 0.3 mg / kg by gavage.
- Control animals received 5 ml of water.
- the excreted urine volume was measured two and five hours after application; the sodium and potassium content was determined by flame photometry, the chloride content was determined mercurimetrically.
- These compounds can also be used to treat diseases caused by disturbed chloride ion transport.
- R3 is a cyclopentane or cyclohexane, substituted by methyl, ethyl, propyl, isopropyl, t-butyl, allyl, vinyl, phenyl or benzyl, where a hydroxyl group may be present as the geminal substituent;
- R a , Rfc, CH 3 , C 2 H5 or R a and R] -. together -CH 2 -CH 2 -,
- R 3 is a cyclopentanone or cyclohexanone
- R 3 is a cycloalkane or cycloalkene with 4-8
- Carbon atoms which can optionally be substituted by a straight-chain or branched alkenyl group having 2 to 4 carbon atoms, a cyclopentanone or cyclopentanol or cyclohexanone or cyclohexanol, which are in the ⁇ -position to the keto or hydroxyl group by C to C 4 alkenyl, C3 or C 4 alkynyl , Benzyl, -CH CH 2 CN, (CH 2 ) 3 NR 5 R5 R 5 equal to or different), CH 2 C00R 4 , CH 2 0R 4 can be substituted, where R 4 can be hydrogen, methyl, ethyl or propyl;
- R5 is hydrogen, an alkyl group having 1 to 3 carbon atoms; a cyclopropyl group, a benzyl group;
- R 7 prolinoyl, CO- (CH 2 ) 0 - 3 -CH 3 ,
- Another object of the present invention is the combination of compounds of general formula I, especially the compounds mentioned by name with loop diuretics - for example furosemide, bumetamides and etacrynic acid.
- the compounds of general formula I can be administered orally or parenterally or as a suppository.
- the compounds are present as active ingredients in conventional dosage forms, e.g. in compositions consisting essentially of an inert pharmaceutical carrier and an effective dose of the active ingredient, e.g. Tablets, dragées, capsules, wafers, powders, solutions, suspensions, emulsions, syrups, suppositories, etc.
- An effective dose of the compounds in the indication claimed according to the invention is between 5 and 100 mg per dose, preferably between 10 and 50 mg, for oral use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/436,220 US5599817A (en) | 1992-11-13 | 1993-11-11 | Xanthine derivatives as diuretic agents |
KR1019950701869A KR950703964A (ko) | 1992-11-13 | 1993-11-11 | 이뇨제로서 사용하기 위한 크산틴 유도체(Xanthine derivatives for use as diuretics) |
SK607-95A SK60795A3 (en) | 1992-11-13 | 1993-11-11 | Diuretic agents |
PL93308992A PL308992A1 (en) | 1992-11-13 | 1993-11-11 | Xantine derivatives as diuretic agents |
AU54650/94A AU5465094A (en) | 1992-11-13 | 1993-11-11 | Xanthine derivatives for use as diuretics |
EP94900128A EP0667777A1 (de) | 1992-11-13 | 1993-11-11 | Xanthinderivate als diuretisches mittel |
JP6511709A JPH08503204A (ja) | 1992-11-13 | 1993-11-11 | 利尿剤としてのキサンチン誘導体 |
NO951887A NO951887D0 (no) | 1992-11-13 | 1995-05-12 | Xantin-derivater som diuretiske midler |
FI952311A FI952311A (fi) | 1992-11-13 | 1995-05-12 | Ksantiinijohdannaiset diureettisena aineena |
BG99638A BG99638A (en) | 1992-11-13 | 1995-05-16 | Derivatives of xanthine as diuretic form |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4238367.6 | 1992-11-13 | ||
DE4238367A DE4238367A1 (de) | 1992-11-13 | 1992-11-13 | Diuretisches Mittel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994011000A1 true WO1994011000A1 (de) | 1994-05-26 |
Family
ID=6472821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/003158 WO1994011000A1 (de) | 1992-11-13 | 1993-11-11 | Xanthinderivate als diuretisches mittel |
Country Status (18)
Country | Link |
---|---|
US (1) | US5599817A (de) |
EP (1) | EP0667777A1 (de) |
JP (1) | JPH08503204A (de) |
KR (1) | KR950703964A (de) |
CN (1) | CN1090493A (de) |
AU (1) | AU5465094A (de) |
BG (1) | BG99638A (de) |
CA (1) | CA2148473A1 (de) |
CZ (1) | CZ123595A3 (de) |
DE (1) | DE4238367A1 (de) |
FI (1) | FI952311A (de) |
HU (1) | HUT72496A (de) |
IL (1) | IL107589A0 (de) |
MX (1) | MX9307082A (de) |
PL (1) | PL308992A1 (de) |
SK (1) | SK60795A3 (de) |
WO (1) | WO1994011000A1 (de) |
ZA (1) | ZA938453B (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0970696A1 (de) * | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Zusammensetzung von Schleifendiuretika und Adenosin A1 Rezeptor Antagonisten |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1386609A1 (de) * | 1998-04-24 | 2004-02-04 | Cv Therapeutics | Adenosin A1 Rezeptor Antagonisten enthaltende Zusammensetzung und Verfahren zur Wiederherstellung der Diuretischen- und Nierenfunktion |
ATE252905T1 (de) * | 1998-04-24 | 2003-11-15 | Biogen Inc | Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
RU2367442C2 (ru) * | 2003-04-25 | 2009-09-20 | Новокардия, Инк. | Способ нормализации мочеиспускания при нарушении функции почек |
JP2007532671A (ja) * | 2004-04-16 | 2007-11-15 | ノヴァカーディア,インク. | アデノシンa1受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法 |
JP2009540003A (ja) * | 2006-06-16 | 2009-11-19 | ノヴァカーディア,インク. | Aa1raの低頻度投与を含む腎機能の長期間にわたる改善 |
WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
WO2010011824A1 (en) * | 2008-07-25 | 2010-01-28 | Concert Pharmaceuticals, Inc. | Novel xanthine compounds |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002551A1 (en) * | 1984-10-26 | 1986-05-09 | United States Of America, Represented By The Unite | Biologically-active xanthine derivatives |
EP0386675A2 (de) * | 1989-03-06 | 1990-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivate |
EP0415456A2 (de) * | 1989-09-01 | 1991-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinverbindungen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1201997A (en) * | 1967-08-04 | 1970-08-12 | Yissum Res Dev Co | New substituted purines and purine derivatives |
US3624215A (en) * | 1970-06-25 | 1971-11-30 | Abbott Lab | 8-substituted theophyllines as anti-anxiety agents |
US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
-
1992
- 1992-11-13 DE DE4238367A patent/DE4238367A1/de not_active Withdrawn
-
1993
- 1993-11-11 WO PCT/EP1993/003158 patent/WO1994011000A1/de not_active Application Discontinuation
- 1993-11-11 KR KR1019950701869A patent/KR950703964A/ko not_active Application Discontinuation
- 1993-11-11 SK SK607-95A patent/SK60795A3/sk unknown
- 1993-11-11 US US08/436,220 patent/US5599817A/en not_active Expired - Fee Related
- 1993-11-11 PL PL93308992A patent/PL308992A1/xx unknown
- 1993-11-11 EP EP94900128A patent/EP0667777A1/de not_active Withdrawn
- 1993-11-11 JP JP6511709A patent/JPH08503204A/ja active Pending
- 1993-11-11 CZ CZ951235A patent/CZ123595A3/cs unknown
- 1993-11-11 CA CA002148473A patent/CA2148473A1/en not_active Abandoned
- 1993-11-11 HU HU9501397A patent/HUT72496A/hu unknown
- 1993-11-11 AU AU54650/94A patent/AU5465094A/en not_active Abandoned
- 1993-11-12 ZA ZA938453A patent/ZA938453B/xx unknown
- 1993-11-12 IL IL10758993A patent/IL107589A0/xx unknown
- 1993-11-12 MX MX9307082A patent/MX9307082A/es unknown
- 1993-11-13 CN CN93114496A patent/CN1090493A/zh active Pending
-
1995
- 1995-05-12 FI FI952311A patent/FI952311A/fi not_active Application Discontinuation
- 1995-05-16 BG BG99638A patent/BG99638A/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002551A1 (en) * | 1984-10-26 | 1986-05-09 | United States Of America, Represented By The Unite | Biologically-active xanthine derivatives |
EP0386675A2 (de) * | 1989-03-06 | 1990-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivate |
EP0415456A2 (de) * | 1989-09-01 | 1991-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinverbindungen |
Non-Patent Citations (2)
Title |
---|
SHIMADA, J. ET AL: "8-(DICYCLOPROPYLMETHYL)-1,3-DIPROPYLXANTHINE: A POTENT AND SELECTIVE ADENOSINE A1 ANTAGONIST WITH RENAL PROTECTIVE AND DIURETIC ACTIVITIES", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 1, 1991, pages 466 - 469 * |
SUZUKI, F. ET AL: "ADENOSINE A1 ANTAGONISTS. 2. STRUCTURE-ACTIVITY RELATIONSHIPS ON DIURETIC ACTIVITIES AND PROTECTIVE EFFECTS AGAINST ACUTE RENAL FAILURE", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 16, 1992, pages 3066 - 3075, XP002055503, DOI: doi:10.1021/jm00094a022 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0970696A1 (de) * | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Zusammensetzung von Schleifendiuretika und Adenosin A1 Rezeptor Antagonisten |
Also Published As
Publication number | Publication date |
---|---|
HU9501397D0 (en) | 1995-06-28 |
HUT72496A (en) | 1996-05-28 |
CA2148473A1 (en) | 1994-05-26 |
CN1090493A (zh) | 1994-08-10 |
DE4238367A1 (de) | 1994-05-19 |
AU5465094A (en) | 1994-06-08 |
JPH08503204A (ja) | 1996-04-09 |
FI952311A0 (fi) | 1995-05-12 |
US5599817A (en) | 1997-02-04 |
BG99638A (en) | 1996-04-30 |
KR950703964A (ko) | 1995-11-17 |
CZ123595A3 (en) | 1995-12-13 |
MX9307082A (es) | 1994-05-31 |
EP0667777A1 (de) | 1995-08-23 |
FI952311A (fi) | 1995-05-12 |
ZA938453B (en) | 1994-05-13 |
IL107589A0 (en) | 1994-02-27 |
PL308992A1 (en) | 1995-09-18 |
SK60795A3 (en) | 1996-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2856393C2 (de) | Arzneimittel zur Behandlung von Morbus Parkinson | |
WO1994011000A1 (de) | Xanthinderivate als diuretisches mittel | |
EP1923073B1 (de) | Kombinationsmedikation mit PDE-5-Inhibitor | |
EP0038438B1 (de) | Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel | |
EP1032572B1 (de) | Pyranone, verfahren zu ihrer herstellung und verwendung | |
DE2520978A1 (de) | Dosierungseinheiten von festen, oral zu verabreichenden arzneiformen, insbesondere von wasserloeslichen xanthin-derivaten | |
DE60315426T2 (de) | Pharmazeutische zusammensetzung enthaltend einen pde4 oder pde3/4 inhibitor und eine histaminrezeptorantagonisten | |
DE69907387T2 (de) | Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis. | |
EP4167996B1 (de) | Metamizolderivate zur prävention und therapie der pulmonalen hypertonie | |
DE2451933C2 (de) | ||
DE3205149C2 (de) | ||
WO1994003173A1 (de) | Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose | |
DE2630015C3 (de) | 4,5,6,7-Tetrahydro-3(4-methoxyphenyl)-indazol und diese Verbindung enthaltende Arzneimittel | |
DE2823267C2 (de) | ||
DE3141970A1 (de) | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen | |
DE2145359B2 (de) | 1-eckige klammer auf buten-(2)ylidenhydrazino eckige klammer zu phthalazinderivate | |
DE4324944A1 (de) | Verwendung von 8-(3-Oxocyclopentyl)-1,3-dipropyl-7H-purin-2,6-dion zur symptomatischen Behandlung der zystischen Fibrose | |
DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
DE4236917A1 (de) | Verwendung von 8-(3-Oxocyclopentyl)-1,3-dipropyl-7H-purin-2,6-dion zur Behandlung von Lungenerkrankungen | |
DE2162590A1 (de) | Bronchialerweiterndes Mittel | |
DE3213579A1 (de) | Arzneimittel mit blutdrucksenkender wirkung | |
DE2936244A1 (de) | Diuretische mittel | |
CH653555A5 (de) | Eine nasal verabreichbare pharmazeutische zusammensetzung. | |
DE2508852A1 (de) | Uricosurische diuretische mittel | |
DE2116214A1 (de) | Zahnputzmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BY CA CZ FI HU JP KR KZ NO NZ PL RO RU SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2148473 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 60795 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1995-1235 Country of ref document: CZ Ref document number: 952311 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994900128 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 257848 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08436220 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994900128 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1995-1235 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1995-1235 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994900128 Country of ref document: EP |